Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 98%
filed 2026-08-06
This is a press release announcing VTEX's second quarter 2026 financial results, dated August 6, 2026. The document discloses key financial metrics including subscription revenue growth of 11.4% (1.3% FXN), GMV growth of 17.8% (7.0% FXN), non-GAAP operating income of $13.8 million, and free cash flow of $12.7 million, along with forward guidance for Q3 and full-year 2026. This is a material earnings announcement that would affect a reasonable investor's assessment of the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Perdoceo Education's second quarter and year-to-date 2026 financial results, including revenue ($435.1M YTD, up 3.0%), operating income ($118.0M YTD, up 14.4%), and earnings per diluted share ($1.60 YTD vs. $1.27 prior year). The press release also provides third quarter and full year 2026 outlook and announces a 13.3% dividend increase to $0.17 per share. This is a material disclosure affecting investor assessment of the registrant's financial performance and capital allocation strategy.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Airbnb issued a Shareholder Letter on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026. The disclosure includes key metrics (revenue of $3.6B with 17% Y/Y growth, net income of $816M, Adjusted EBITDA of $1.3B), detailed business performance analysis, and forward guidance for Q3 and full-year 2026. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
The filing discloses Manitowoc's second-quarter 2026 earnings results via a press release (Exhibit 99.1) under Item 2.02. The press release reports net income of $0.39 per diluted share, net sales of $594.9 million (up 10.3% YoY), adjusted EBITDA of $48.9 million (up 85.9% YoY), and raised full-year 2026 guidance. This is a standard quarterly earnings announcement with material financial metrics and forward guidance that would affect investor assessment of the company's performance and prospects.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Corsair's financial results for the second quarter ended June 30, 2026. The press release (Exhibit 99.1) announces quarterly financial highlights including gross profit, operating income, net income, revenue, adjusted EBITDA, and EPS, along with forward guidance for Q3 and full-year 2026. The disclosure is material as it provides comprehensive financial performance data and updated guidance that would affect investor assessment of the company's financial condition and prospects.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
IN8bio issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, including cash position ($18.0M), R&D expenses ($2.5M), G&A expenses ($2.4M), and net loss ($4.8M or $0.25 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures. The financial statements and operational metrics are material to investors assessing the company's financial condition and progress.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-08-06
Item 1.01
Quanta Services issued $2.0 billion in aggregate principal amount of senior unsecured notes across three tranches with maturities in 2029, 2033, and 2036 pursuant to an underwriting agreement with major financial institutions.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a quarterly earnings release for Q2 2026 disclosing financial results including revenue of $64.1 million (7.6% YoY increase), gross profit, net loss of $(12.2) million (including an $11.0 million goodwill impairment), and Adjusted EBITDA of $2.8 million. The filing includes complete financial statements and management commentary, which is the standard format for an earnings disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Item 2.02 discloses Nano Dimension's second quarter 2026 financial results via a press release titled "Nano Dimension Reports Financial Results for the Second Quarter 2026." The filing includes detailed GAAP and non-GAAP financial metrics (revenue of $29.0 million, gross margin of 45.9%, net loss from continuing operations of $6.8 million) and is incorporated by reference into the company's registration statements. This is a standard quarterly earnings release disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-06
Item 1.01
ARKO Corp.'s subsidiary APC entered into an Asset Purchase Agreement on August 4, 2026, to acquire the U.S. Petroleum Partners business, a vertically integrated fuel supply and distribution platform with two fuel terminals, supply rights to 400+ dealer locations, and a fleet of vehicles, for $205 million in cash plus $30 million in stock consideration with potential earn-out adjustments.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release (Exhibit 99.1) announces quarterly financial results including total investment income of $37.0 million, net investment income of $18.2 million ($0.43 per share), net asset value of $502.6 million ($11.91 per share), and portfolio details. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release incorporated by reference, which is the standard format for earnings disclosures by BDCs and investment companies.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 ended June 30, 2026. The Item 2.02 disclosure explicitly states that Outset Medical issued a press release announcing financial results for the quarter, with the press release furnished as Exhibit 99.1. The exhibit contains detailed financial statements, revenue metrics ($31.6M, up 1% YoY), gross margin expansion to 42%, net loss of $18.0M, and full-year 2026 guidance of $125-130M revenue. This is a standard quarterly earnings announcement material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-06
Item 1.01
ARKO Petroleum entered into an Asset Purchase Agreement on August 4, 2026, to acquire the U.S. Petroleum Partners business, a vertically integrated fuel supply and distribution platform with two fuel terminals, supply rights to 400+ dealer locations, and a fleet of vehicles, for $205 million in cash plus $30 million in stock consideration with potential earn-out adjustments.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Item 2.02 discloses Nerdy Inc.'s Q2 2026 earnings results via press releases furnished as Exhibits 99.1 and 99.2. The exhibits contain a comprehensive earnings release with financial highlights, revenue of $43.3 million, net loss of $6.9 million, non-GAAP adjusted EBITDA loss of $0.9 million, and forward guidance for Q3 and full-year 2026. This is a standard quarterly earnings disclosure material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Resmed disclosed quarterly and fiscal year 2026 financial results for the period ended June 30, 2026, reporting revenue growth of 9% to $1.5 billion in Q4 and 10% to $5.7 billion for FY2026, with detailed financial statements and EPS metrics included in the earnings announcement.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-06
Item 8.01
Resmed announced a quarterly cash dividend of $0.66 per share, representing a 10% increase from the previous dividend, with a record date of August 20, 2026 and payment date of September 24, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Hyperfine's second quarter 2026 financial results. The Item 2.02 filing announces Q2 2026 revenues of $3.9 million (up 44.8% YoY), gross profit of $2.0 million with 50.7% gross margin, and a net loss of $9.3 million ($0.09 per share). The press release also provides full-year 2026 guidance and business highlights including CE Marking approval and European launch. The disclosure includes condensed consolidated financial statements (balance sheet, income statement, and cash flow statement) and is material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a standard earnings release disclosing Q2 2026 financial results for Evommune, Inc., filed under Item 2.02 (Results of Operations and Financial Condition). The press release includes unaudited condensed consolidated statements of operations and balance sheets, showing net loss of $32.2 million and $53.9 million for Q2 and H1 2026 respectively, along with cash position of $288.0 million as of June 30, 2026. The disclosure is material to investors assessing the company's financial condition and cash runway through 2028.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Fidus Investment Corporation issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, including total investment income of $43.5 million, net investment income of $18.7 million ($0.49 per share), and NAV of $738.5 million ($19.46 per share).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-06
Item 7.01
Fidus Investment Corporation declared a base dividend of $0.43 per share and a supplemental dividend of $0.07 per share (totaling $0.50 per share) payable on September 29, 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a straightforward earnings release for Q2 2026 filed under Item 2.02. The press release (Exhibit 99.1) discloses quarterly financial results including R&D expenses ($15.2M vs $9.4M YoY), G&A expenses ($5.4M vs $4.3M YoY), net loss ($17.8M vs $12.3M YoY), and cash position ($318.9M). The filing also includes selected balance sheet and statement of operations data, which are typical components of an earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a standard earnings release disclosing quarterly and six-month financial results for the period ended June 30, 2026. The press release reports key financial metrics including cash position ($970.9 million), R&D expenses ($31.0 million for Q2), G&A expenses ($11.0 million for Q2), and net loss ($22.0 million for Q2), along with condensed balance sheets and statements of operations. The disclosure is material to investors assessing the company's financial condition and cash runway as a clinical-stage biopharmaceutical company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-06
Item 2.02
ARKO Petroleum Corp. disclosed financial results for Q2 2026 and the six-month period ended June 30, 2026, reporting net income of $12.2 million and Adjusted EBITDA of $39.8 million, with reaffirmed full-year strategic guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-06
Item 2.02
ARKO Petroleum disclosed Q2 2026 financial results ended June 30, 2026, reporting net income of $12.2 million and Adjusted EBITDA of $39.8 million, with reaffirmed full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
ICF International announced its financial results for the second quarter ended June 30, 2026, including quarterly revenue of $474.5 million, net income of $26.9 million, and diluted EPS of $1.49, with reaffirmed full-year 2026 guidance ranges for revenue, GAAP EPS, and Non-GAAP EPS.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-06
Item 8.01
ICF International declared a quarterly cash dividend of $0.14 per share payable on October 9, 2026, to shareholders of record as of September 4, 2026, reflecting the company's capital allocation policy and confidence in its financial position.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses quarterly financial results including R&D expenses ($21.9M), G&A expenses ($5.0M), net loss ($25.0M), and cash position ($349.4M), along with condensed balance sheets and statements of operations. The disclosure is material to investors as it provides the registrant's financial performance and runway guidance (expected to fund operations into 2029).
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 74%
filed 2026-08-06
Item 1.01
On August 3, 2026, Beachbody entered into Amendment No. 2 to its Credit Agreement with Tiger Finance, LLC, materially restructuring the Company's debt facility. The amendment eliminates the billings fixed charge coverage ratio covenant, reduces the minimum cash threshold by approximately $7 million, increases the interest rate to SOFR plus 9.00%, and conditionally modifies other financial covenants—changes that reflect financial stress and renegotiation of debt terms material to investors.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Onto Innovation's fiscal second quarter ended June 30, 2026, filed on August 6, 2026. The Item 2.02 disclosure announces quarterly financial results including record revenue of $343 million (up 18% sequentially and 35.3% year-over-year), gross margin of 53.4%, operating income of $63.6 million, and diluted EPS of $1.21. The company also provided forward guidance for Q3 2026. The earnings release is attached as Exhibit 99.1 and contains detailed financial highlights, operating results, and management commentary on business momentum.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
JFrog issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing total revenues of $163.8 million (up 29% YoY), cloud revenues of $87.5 million (up 53% YoY), and providing forward guidance for Q3 and full-year 2026. This is a standard quarterly earnings release with comprehensive financial metrics and operational highlights, clearly falling under Item 2.02 disclosure of results of operations and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
CleanSpark disclosed financial results for its fiscal quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly revenues ($138.0 million), net loss ($239.8 million or $0.89 per share), and Adjusted EBITDA ($113.0 million loss), along with balance sheet highlights and forward-looking guidance. This is a standard quarterly earnings release material to investors assessing the company's financial performance and operational trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a quarterly earnings release for Q2 2026 disclosing financial results (net loss of $22.3 million, R&D expenses of $18.0 million, G&A expenses of $6.2 million, and cash position of $227.1 million) along with business highlights and clinical trial updates. The filing explicitly states it is furnished under Item 2.02 of Form 8-K and includes the full press release as Exhibit 99.1, which is the standard format for earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a classic earnings release disclosure under Item 2.02. The company issued a press release on August 6, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including consolidated balance sheets and statements of operations. The filing includes detailed financial metrics (R&D expenses of $48.7M, G&A expenses of $26.4M, net loss of $159.0M) and material clinical program updates (positive Phase 3 Emerge results for DT120 ODT in MDD, cash position of $1.1 billion). This is material to investors as it discloses quarterly financial performance and significant clinical milestones for a late-stage biopharmaceutical company.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-06
EX-99.1
Alexandre Arnault resigned from his position as Director on the Board of Directors effective August 6, 2026, due to professional commitments. The press release explicitly announces his departure and notes he served for five years during an important chapter of the company's development. This is a clear executive departure requiring disclosure under Item 5.02 of Form 8-K equivalents, and is material given his tenure and the company's acknowledgment of his value to the board.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Alector disclosed its second quarter 2026 financial results on August 6, 2026, via a press release (Exhibit 99.1) attached to the 8-K Item 2.02. The disclosure includes consolidated statements of operations showing collaboration revenue of $3.3 million, operating expenses of $27.7 million, and a net loss of $22.9 million ($0.21 per share) for Q2 2026, along with balance sheet data and cash position of $172.8 million. This is a standard quarterly earnings release material to investors assessing the company's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
CytomX issued a press release on August 6, 2026, reporting unaudited financial results for the three and six months ended June 30, 2026, including condensed balance sheets and statements of operations. The disclosure includes Q2 2026 revenue ($1.4M), operating expenses ($25.2M), cash position ($330.3M), and cash runway projections, along with pipeline program updates and corporate developments. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
AVITA Medical issued a press release on August 6, 2026, announcing Q2 2026 financial results, including record revenue of $21.7 million (18% YoY growth), improved gross margins, and raised full-year 2026 revenue guidance to $86–$89 million. The disclosure includes consolidated financial statements and forward guidance, which are hallmarks of an earnings release under Item 2.02. The company also announced expectations to reach cash flow breakeven in Q4 2026, a material milestone for investor assessment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Relay Therapeutics amended its at-the-market (ATM) offering agreement with TD Securities on August 6, 2026, increasing the authorized offering size from $250 million to approximately $463 million, allowing the company to sell an additional $213 million in shares through an unregistered equity program.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Relay Therapeutics announced second quarter 2026 financial results on August 6, 2026, reporting revenue of $0.4 million, R&D expenses of $76.5 million, G&A expenses of $14.7 million, a net loss of $83.7 million ($0.41 per share), and a cash position of $911 million, along with clinical progress updates.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-06
Item 1.01
CarGurus entered into a First Amendment to its Credit Agreement on August 6, 2026, extending the maturity date from September 26, 2027 to August 6, 2031, reducing revolving commitments from $400 million to $200 million, increasing the Cash-Capped Incremental Facility cap, and adding a new leverage covenant of 6.25:1.00 Consolidated Total Gross Leverage Ratio.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
CarGurus announced Q2 2026 financial results on August 6, 2026, reporting revenue of $251.0 million (13% YoY growth), GAAP net income of $49.2 million, and adjusted EBITDA of $84.7 million, along with forward guidance for Q3 and full-year 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
Xenon Pharmaceuticals reported Q2 2026 financial results for the three and six months ended June 30, 2026, disclosing a net loss of $110.7M, R&D expenses of $99.2M, G&A expenses of $23.9M, other income of $11.8M, and a cash position of $1.245B, along with clinical development updates on its pipeline programs including azetukalner.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The Item 2.02 disclosure explicitly states that Lineage "issued a press release announcing financial results for the quarter ended June 30, 2026," with the full press release furnished as Exhibit 99.1. The exhibit contains detailed financial results including revenues ($1.1M), operating expenses ($10.0M), operating loss ($8.9M), and net income ($1.5M), along with balance sheet highlights and comprehensive business updates on clinical programs and pipeline progress.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Cytokinetics' Q2 2026 financial results, including total revenues of $28.6 million (with $25.3 million from MYQORZO product sales), R&D expenses of $97.8 million, SG&A expenses of $104.4 million, and a net loss of $198.8 million. The press release is furnished as Exhibit 99.1 and includes detailed financial metrics, cash position ($1.7 billion), and updated 2026 guidance, which are material to investors assessing the company's financial performance and runway.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Organogenesis's Q2 2026 financial results via press release furnished as Exhibit 99.1. The filing reports net revenue of $42.8 million (down 58% YoY), net loss of $96.3 million (vs. $9.4 million loss in Q2 2025), and significantly reduced full-year 2026 guidance (62-68% revenue decline). The material deterioration in financial performance—including a $86.9 million increase in net loss and substantial revenue contraction—would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Guardian Pharmacy Services issued a press release on August 6, 2026 reporting Q2 2026 financial results for the quarter ended June 30, 2026, including revenue of $351.8 million, net income of $22.1 million, and adjusted EBITDA of $29.7 million. The company also raised its full-year 2026 guidance. This is a standard quarterly earnings release furnished under Item 2.02 and attached as Exhibit 99.1, which is the archetypal earnings_release event.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 financial results. The Item 2.02 disclosure states that Navient "issued an informational press release announcing its financial results for the quarter ended June 30, 2026" and posted complete financial results to its website. The attached exhibits (EX-99.1 and EX-99.2) contain the formal earnings announcement with GAAP net income of $25 million ($0.26 diluted EPS), Core Earnings of $27 million ($0.29 diluted EPS), segment results, and detailed financial metrics. This is a material quarterly earnings disclosure typical of Item 2.02 filings.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
TechTarget issued a press release on August 6, 2026 announcing financial results for Q2 and H1 2026, disclosing revenues of $116.1 million (Q2) and $222.2 million (H1), net losses, Adjusted EBITDA metrics, and reiterated 2026 growth guidance. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, meeting the definition of earnings_release.
View raw filing on EDGAR →
8-K
Earnings release
confidence 99%
filed 2026-08-06
Item 2.02
QuinStreet issued a press release on August 6, 2026 announcing financial results for the fourth quarter and full fiscal year ended June 30, 2026. The disclosure includes record quarterly and annual revenue ($373.9M and $1.3B respectively), record net income ($19.1M and $81.2M), and record adjusted EBITDA ($41.4M and $112.5M), along with forward guidance for Q1 and FY2027. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Turtle Beach Corporation issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, including net revenue of $56.4 million, net loss of $7.3 million, and adjusted EBITDA of $1.3 million. The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes quarterly financial statements and full-year 2026 guidance reaffirmation.
View raw filing on EDGAR →